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A genetic diagnosis facilitates personalized cancer treatment and clinical care of
relatives at risk, however, although 25% of colorectal cancer cases are familial, around
95% of the families are genetically unresolved. In this study, we performed gene
panel analysis on germline DNA of 32 established or candidate colorectal cancer
predisposing genes in 149 individuals from either families with an accumulation of
colorectal cancers or families with only one sporadic case of very early onset colorectal
cancer (≤40 years at diagnosis). We identified pathogenic or likely pathogenic genetic
variants in 10.1% of the participants in genes such as APC, POLE, MSH2 or PMS2.
The MSH2 variant, c.2168C>T, p.(Ser723Phe) was previously described as a variant of
unknown significance, but we have now reclassified it to be likely pathogenic. The POLE
variant, c.1089C>A, p.(Asn363Lys) was identified in a patient with three metachronous
colorectal cancers from age 28 and turned out to be de novo. One pathogenic PMS2
variant was novel. We also identified a number of highly interesting variants of unknown
significance in APC, BUB1, TP53 and RPS20. The RPS20 variant is novel and was found
in a large Amsterdam I positive family with a multi tumor phenotype including 12 cases
of CRC from as early as age 24. This variant was found to segregate with cancer in the
family and multiple in silico tools predict it to be pathogenic. Our data further support
the shift from phenotypic-based cancer panels to large panels including all established
genes involved in hereditary cancer syndromes or (targeted) whole genome sequencing.
Additionally, identification of a likely disease-predisposing variant in RPS20 expands the
phenotypic spectrum of RPS20-related cancers and emphasize that this gene is relevant
to include in colorectal cancer gene panels.
Keywords: hereditary colorectal cancer, gene panel analysis, familial cancer, oligogenic inheritance, early onset
colorectal cancer, RPS20
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INTRODUCTION
Colorectal cancer (CRC) is one of the most frequent types
of cancer worldwide and is now the second most common
cancer in Denmark. Approximately 20% to 30% of the
cases report a family history with other cases of CRC,
however, in more than 95% of the affected cases a genetic
etiology cannot be identified (Schubert et al., 2019). The
families are highly heterogeneous regarding phenotypes,
inheritance patterns and overall lifetime cancer risk,
making genetic counseling and surveillance a challenge.
An established genetic diagnosis facilitates personalized
cancer treatment, and surveillance of affected and unaffected
carriers, emphasizing the importance of identifying the genetic
background of the disease.
Traditionally, Danish patients or families suspected of having
hereditary CRC, for example due to familial aggregation
of CRC, early-onset disease or multiple primary hereditary
non-polyposis colorectal cancer (HNPCC) associated tumors,
have been offered genetic counseling and genetic test of the
Lynch Syndrome-predisposing mismatch repair (MMR) genes
(MLH1, MSH2, MSH6, PMS2) and EPCAM, and in case of
several colonic adenomas in addition APC and MUTYH. In
the past 5 years a larger gene panel consisting of 17 CRC-
predisposing genes (APC, AXIN2, BMPR1A, EPCAM, GREM1,
MLH1, MSH2, MSH3, MSH6, MUTYH, NTHL1, PMS2, POLD1,
POLE, PTEN, SMAD4 and STK11) has usually been analyzed,
however, the great majority of cases are still genetically
unresolved.
Lack of a genetic diagnosis is a worldwide issue in familial
and early onset CRC and has led to many studies utilizing
larger cancer panels in search of genetic explanations. The
number of analyzed genes has varied, but depending on
the cohort and previous genetic analyses, a monogenetic
etiology – often including variants in genes with uncertain
clinical impact and low- or moderate risk variants – has been
identified in up to 22% of the patients analyzed, with the
highest diagnostic yield in younger patients (Chubb et al.,
2015; Mork et al., 2015; Hansen et al., 2017; Pearlman
et al., 2017; Yurgelun et al., 2017; Dominguez-Valentin et al.,
2018; Martin-Morales et al., 2018; Stoffel et al., 2018).
However, some studies have shown a very limited diagnostic
yield when analyzing well-established cancer predisposition
genes suggesting that other genetic inheritance patterns or
mechanisms should be sought. Several possible disease-causing
genetic mechanisms have been proposed including variants in
not yet identified highly penetrant cancer genes, mosaicism,
regulatory- and deep intronic variants in known cancer
genes, epigenetic alterations, or di-, oligo- or polygenic
inheritance (Schubert et al., 2019); further studies exploring these
mechanisms are warranted.
In this study, we aimed at identifying rare or novel germline
variants in 32 established or suggested cancer predisposition
genes in a cohort of highly selected Danish patients with
either very early onset sporadic CRC (i.e., ≤40-years-old) or
in families with familial CRC and without identified MMR-
deficiency.
MATERIALS AND METHODS
Patients
The participants were recruited from two cohorts: (1). Families
with familial CRC (the ‘Familial CRC cohort’) and (2). Families
with only one case of early onset CRC (the ‘Early onset CRC
cohort’). Family data was extracted from the Danish Hereditary
Non-Polyposis Colorectal Cancer (HNPCC) registry (Clinical
Research Centre, Copenhagen University Hospital, Hvidovre,
Denmark). The registry covers all parts of Denmark and
has, since 1991, records of all families with, or suspected of
having, hereditary CRC. In addition, some patients/families
were identified through genetic counseling in Department of
Clinical Genetics, Rigshospitalet, and invited/included in the
study. They fulfilled the same inclusion criteria. For both cohorts,
we included patients without known Lynch Syndrome, or not
previously tested. Patients/families with previously identified
variants of unknown significance in cancer genes were kept in
the study in order to search for alternative explanations. Previous
identification of pathogenic variants in other CRC-predisposing
genes caused exclusion.
The patients included in this study had gene panel analyses
performed by January 1st, 2020. Flow diagram of the inclusion
process can be found in Figure 1.
The Familial CRC Cohort
We received data on all Amsterdam I or II positive families
(i.e., families with at least three cases of CRC (= Amsterdam
I) or HNPCC-associated cancers (cancer of the endometrium,
small intestine, ureter or renal pelvis = Amsterdam II), affecting
at least two successive generations, with one relative diagnosed
before the age of 50 years; one should be a first-degree
relative of the other two and familial adenomatous polyposis
(FAP) should be excluded) without, or not tested for, Lynch
Syndrome. A total of 249 families fulfilled the search criteria
as of March 24th, 2015. Based on pedigrees, pathology reports
and previous molecular analyses, we selected the families most
likely to have a monogenic, non-MMR high risk variant, i.e.,
families with a high number of affected individuals with CRC
(preferably synchronous/metachronous CRC), multiple primary
cancers or colonic adenomas (preferably advanced adenomas, i.e.,
size ≥ 10 mm., with high grade dysplasia or villous/tubulovillous
morphology), young age at onset and a clearly dominant
inheritance pattern without unaffected generations, and with
available DNA or a living affected individual. A total of 181
families were selected for inclusion. All recruited subjects had
to fulfill our inclusion criteria by having (1). Any type of cancer
or (2). Colonic adenomas (either ≥3 colorectal adenomas or ≥1
advanced, colorectal adenoma).
The Early Onset CRC Cohort
We received data on all families with only a single case of CRC
before age 50, and without a family history of CRC in first
degree relatives and grandparents (n = 596 patients as of February
15th, 2017). The search criteria only included patients without
genetically identified Lynch Syndrome, or not previously tested.
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FIGURE 1 | Flow diagram of the inclusion process.
Patients with CRC between 18 to 40 years at time of diagnosis
(n = 198) were recruited.
Inclusion and Follow Up
After updating the pedigree with relevant clinical information,
some families did not fulfill the inclusion criteria. In the early
onset CRC cohort this could be due to a newly developed case
of CRC in the family, resulting in CRC in a first or second
degree relative, and in the familial CRC cohort it could be due
to original inadequate family data, such as a case of polyposis
not reported to the registry. Since family history is a process of
constant development, we kept these families in the study.
All living patients received written and oral information as
well as genetic counseling, and a written informed consent
was obtained. Ethical approval was obtained from the Danish
Committee on Health Research Ethics (reference: H-4-2014-050).
In total, we included 149 individuals: 50 patients with early
onset CRC and 99 patients from 85 families with familial CRC.
Characteristics of the participants are shown in Table 1.
Next Generation Sequencing Analysis
DNA Extraction
Genomic DNA was extracted from whole blood samples
using ReliaPrep Large Volume HT gDNA Isolation Kit
(Promega, Madison, WI, United States) using a Tecan
Freedom EVO HSM2.0 Workstation according to the
manufacturer’s instructions.
Sequencing
The following 32 genes were examined by next-generation
sequencing (NGS): APC (NM_000038), AXIN2 (NM_004655),
BLM (NM_000057), BMPR1A (NM_004329, BRCA1
(NM_007294, BRCA2 (NM_000059), BUB1 (NM_004336),
CDH1 (NM_004360), CHECK2 (NM_007194), EXO1
(NM_006027), FAN1 (NM_014967), FOCAD (NM_017794),
GALNT12 (NM_024642), IPMK (NM_152230), MLH1
(NM_000249), MLH3 (NM_014381), MSH2 (NM_000251),
MSH3 (NM_002439), MSH6 (NM_000179), MUTYH
(NM_001128425), NTHL1 (NM_002528), PMS1 (NM_000534),
PMS2 (NM_000535), POLD1 (NM_002691), POLE
(NM_006231), PTEN (NM_000314), RINT1 (NM_021930),
RPS20 (NM_001146227), SMAD4 (NM_005359), SMAD9
(NM_001127217), STK11 (NM_000455), TP53 (NM_000546).
Target DNA sequences were captured using biotinylated oligos
provided through Roche NimbleGen (Roche, Basel, Switzerland).
The oligos were designed to capture all exons, including 50 bp
of flanking intronic sequence. Library was constructed using
1400 ng of genomic DNA. The DNA was fragmented into an
average size of 400 bp using a Covaris S2 AFA ultrasonicator.
The trimming, 3′-adenylation and adaptor ligations were
done on a Sciclone G3robot (Perkin Elmer, Waltham, MA,
United States) using Illumina-compatible KAPA library DNA
adaptors (Roche Diagnostics, Basel, Switzerland). Sequence
capture was performed using the single capture protocol as
described by Roche NimbleGen, where 6 to 12 samples are
multiplexed before hybridization. Finally, 2× 151-bp paired-end
sequencing was performed on the Illumina MiSeq platform to
an average depth of >50X (range 54.2–5893.4X) with a coverage
of at least 20X in >98% of the targeted nucleotides and 30X in
>97% of the targeted nucleotides.
Data Processing
Sequencing reads were trimmed and mapped to human reference
genome hg19/GRCh37 using BWA-MEM v0.7.15 software (Li,
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TABLE 1 | Clinical characterization of the participants.
All N = 149 Early onset
CRC cohort
N = 50
Familial CRC
cohort N = 85
Number of participants 149 50 99
Number of families 135 50 85
Amsterdam I positive 75 – 75
Amsterdam II positive 9 – 9
Do not fulfill Amsterdam I/II criteria 1 50 1
Gender and age at diagnosis
Male 67 23 44
Female 82 27 55
Median age at first diagnosis (range) 46 years
(22–78)
36 years
(28–40)
52 years
(22–78)
Results of genetic testing
Number of patients/families with pathogenic/likely pathogenic variants (%) 15/149 (10.1%) 5/50 (10%) 9/85 (10.6%)
Number of clinically actionable variants 6 3 3
Number of patients/families with clinically actionable variants (%) 8 (5.4%) 4 (8%) 3 (3.5%)
Cancer diagnosis
Right-sided colon cancer1 46 17 29
Left-sided colon cancer2 55 15 40
Rectal cancer3 46 16 30
Colorectal cancer, unspecified 5 3 2
Gynecological cancer4 7 0 7
Breast cancer5 3 0 3
Other gastrointestinal cancers6 5 1 4
Other cancers7 7 1 6
Only adenomas8 2 0 1
Synchronous/metachronous CRC 13 1 12
Multiple (i.e., >3) primary tumors 3 0 3
Polyps
No adenomas detected 91 43 48
1–9 adenomas 53 (median 2) 7 (median 1) 46 (median 2,5)
>10 colonic adenomas9 3 0 2
Number of high-grade dysplastic adenomas 5 1 4
>10 serrated lesions 4 1 3
Has ≥1 relative(s) with >10 colonic adenomas 5 0 4
Tumor data
Number of patients/families with IHC analysis performed 118/149
(79.2%)
45/50 (90%) 73/85 (85.9%)
Percentage of patients/families with abnormal IHC 12.7% (15/118) 17.8% (8/45)10 9.6% (7/73)11
Previous genetic analyses at time of inclusion
MMR analysis in the index person 109 (73.2%) 41 (82%) 68 (68.7%)
No previous MMR analysis in the index person or a relative 16 (10.7%) 9 (18%) 7 (8.2%)
Family history
≥1 sibling(s) or child(ren) with CRC <50 years (%) 25 0 25
≥1 sibling(s) or child(ren) with any cancer <60 years 46 1 43
Both parents diagnosed with CRC (%) 6 0 6
Mean number of persons with CRC in the family (1st–3rd degree relatives (range) 2.8 (1–7) 1.06 (1–2) 3.7 (1–7)
Cases of basal cell carcinomas were not included in this table. 1: Adenocarcinomas located in cecum, appendix, ascending- or transverse colon. 2: Adenocarcinomas
located in the splenic flexure, descending colon or sigmoid colon. 3: Only adenocarcinomas. 4: One vulvar cancer (no other cancers), four endometrial cancers (two
persons also had CRC, one person also had CRC and breast cancer and one person also had thyroid cancer) and two ovarian cancers (one also had CRC and breast
cancer). 5: One person also had CRC, one person also had endometrial cancer and one person also had both CRC and ovarian cancer. 6: One duodenal cancer, one ileal
cancer, one esophageal cancer (squamous carcinoma), one carcinoma at the major duodenal papilla, one hepatic cancer (a hepatocellular carcinoma). All patients also
had CRC except the patient with duodenal cancer, who had >100 colonic adenomas. 7: Two persons had bladder cancer, one person had prostate cancer, one person
had chronic lymphatic leukemia and one person had melanoma; they all also had CRC. One person had thyroid cancer and endometrial cancer. 8: Another person from
the same family with three metachronous CRCs were also included. 9: Two persons from the same family had >100 and 25 colonic adenomas, respectively. Another
person had 20 colonic adenomas. 10: Two persons with lack of PMS2 expression had pathogenic PMS2 variants. 11: In seven persons, IHC analysis revealed absence
of one or more MMR-proteins, however, they all had a relative with a normal IHC analysis. Two persons had MLH1 promoter methylation.
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2013). Alignment quality control was performed with mosdepth
v0.2.4 (Pedersen and Quinlan, 2018) for all target regions. Using
GATK v4.1.0.0 suite (McKenna et al., 2010) alignment files were
pre-processed and germline variants were called (Poplin et al.,
2017). Variant files were filtered to exclude variants covered by
<10 reads or called in <20% of the sequencing reads.
Ingenuity Variant Analysis
Called variants were filtered using Ingenuity Variant Analysis
(IVA1). Firstly, variants with call quality < 20, read depth < 10 or
variant allele frequency (VAF) < 15 were disregarded. Secondly,
variants with an allele frequency > 5% of the public variant
database including 1000 genomes project2, ExAC3, gnomAD4
or NHLBI ESP exomes5, unless established as a pathogenic
common variant, were excluded. Variants with a minor allele
frequency (MAF) between 0.5% and 5% in any subpopulation
in gnomAD were not further analyzed unless a class 4 or 5
variant were detected in a patient in a gene known to cause
autosomal recessive cancer. Thirdly, variants in coding regions
(including missense variants regardless of in silico prediction and
synonymous variants) and splice-site variants (±10 bp) were
kept for further analysis, as well as variants listed in ClinVar,
with gain of function established in the literature or with a
CADD score > 20.
Variant Classification
All variants identified after IVA processing were reviewed
and classified according to the ACMG-AMP guidelines
(Richards et al., 2015). We used the following five-class
system: 1 = Not pathogenic/no clinical significance, 2 = Likely
not pathogenic/little clinical significance, 3 = Uncertain,
4 = Likely Pathogenic, 5 = Pathogenic (Plon et al., 2008). Variant
classification by expert panels such as ENIGMA6 or InSiGHT7
were followed unless new knowledge had emerged. All variants
were analyzed manually and evaluated using different tools
or databases such as Alamut Visual8 including in silico splice
prediction, LOVD9, ClinVar10, COSMIC11 and literature search
in PubMed12.
Validation of Variants
All pathogenic and likely pathogenic variants as well as all
variants in Table 3 were validated by visual inspection using the
Integrative Genomics Viewer13 (Robinson et al., 2011), and all
variants used in a clinical setting were validated from a new blood
sample, either by NGS analysis or by Sanger sequencing.
1http://ingenuity.com
2http://www.1000genomes.org
3http://exac.broadinstitute.org
4http://gnomad.broadinstitute.org
5http://evs.gs.washington.edu/EVS
6http://enigma.ini.usc.edu/
7https://insight-database.org/
8https://www.interactive-biosoftware.com
9https://www.lovd.nl/
10https://www.ncbi.nlm.nih.gov/clinvar/
11https://cancer.sanger.ac.uk/cosmic
12https://pubmed.ncbi.nlm.nih.gov/
13https://software.broadinstitute.org
RPS20 Segregation Analysis
In one family member from family 92, the RPS20 c.98A>T
variant was identified in a clinical setting in another department
of clinical genetics during the time our study was running.
In the rest of the tested family members, RPS20 c.98A>T
segregation analysis was performed by Sanger sequencing
(primer sequences are available upon request) when possible.
For some of the family members only non-malignant formalin-
fixated paraffin-embedded (FFPE) tissue samples were available,
and some of those were of a quality that did not allow Sanger
sequencing, so NGS was used instead. One tissue sample failed
with both methods.
Long Range PCR
For verification of the PMS2 variant c.2275+1G>C long range
PCR (LR-PCR) was performed according to the instructions
provided in the LR-PCR Kit (TaKaRa, Tokyo, Japan) using
primers and conditions as previously described (Vaughn et al.,
2010). A second set of primers was used for nested PCR
avoiding polymorphisms located in the primer sequences.
The primer sequences were tested using SNPCheck14 and are
available upon request.
Immunohistochemical Analysis
Formalin fixed, paraffin-embedded samples of CRC or
adenomas were selected for immunohistochemical studies.
Immunohistochemical evaluation, on 3 µm thick sections, was
done using the following Ready-to-use antibodies MLH1 (clone
ES05), PMS2 (clone EP51, MSH2 (clone FE11) and MSH6
(EP49) from Agilent following the manufacturer’s instructions.
The staining took place on the Omnis from Agilent utilizing
the EnVision Flex + detection kit (GV800). The sections were
counterstained with hematoxylin.
Some samples have been analyzed in other departments
of pathology, and historically only MLH1 and MSH2 or
MLH1, MSH2, and MSH6 were analyzed. These samples
might have been analyzed using other kits, however, all
samples have been analyzed as part of a clinical evaluation by
experienced pathologists.
Interpretation of IHC Stainings
The IHC stainings were interpreted by trained colorectal
pathologists as either positive (retained nuclear staining in any
number of tumor cells) or negative (complete loss of nuclear
staining in all tumor cells). Normal colonic crypt epithelium
adjacent to the tumor, lymphoid cells and stromal cells served as
internal positive controls. In addition, on slide positive controls
are a routine practice in our IHC laboratory.
RESULTS
We identified 12 pathogenic or likely pathogenic variants in 15
patients (10.1% of the included patients), listed in Table 2. High
risk variants in MSH2, POLE and APC were identified in 3/85
14https://secure.ngrl.org.uk/SNPCheck/
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TABLE 2 | Pathogenic and likely pathogenic variants.
Family ID (pt.ID) Gene Transcript
variant
Protein variant Cancer localization and adenomas (age) Family history1
High risk variants
14 (14;16 and 14;20) APC c.289G>A p.(Gly97Arg) 14;16: Duodenal cancer (78), IHC = n/a.
>100 colonic adenomas.
14;20: Transverse colon cancer (46), IHC = n/a. 25
colonic adenomas.
Sister A+: Four primary colon cancers (57), <10 colonic
adenomas and a hepatic mucinous
cystadenocarcinoma (69). Also had Caroli disease.
Sister B?: Breast cancer (55).
Mother?: Colon cancer (66).
Mat. 2DR?: Testicular cancer (68).
165 (165;10) MSH2 c.2168C>T p.(Ser723Phe) Ascending colon cancer (47), IHC = MSH2 absent.
Cancer in the major duodenal papilla (51),
IHC = MLH1/PMS2 absent (MLH1 promoter
methylation analysis showed methylation). 2 advanced
adenomas.
Daughter+: Rectal cancer (25), 2 advanced, colonic
adenomas.
Mother−: Transverse colon cancer (44) and 1
advanced, colonic adenoma.
Mat. 2/3DR−: Several cases of CRC (58–80).
309 (309;10) PMS2 c.736_741delins
TGTGTGTGAAG
p.(Pro246Cysfs*3) Cecal cancer (29), IHC = PMS2 absent. Mother?: Breast cancer (68), endometrial cancer (73)
and one advanced TA.
Pat. 2DR?: Cervical cancer (50)
409 (409;10) PMS2 2275+1G>C p.(?) Ascending colon cancer (36), IHC = PMS2 absent. No cancers in first degree relatives.
27 (27;10) POLE c.1089C>A p.(Asn363Lys) Ascending colon cancer (28), IHC = Intact.
Synchronous colorectal cancer (40).
Mother−: Malignant melanoma (68) and lung cancer
(84).
Father−: Colon cancer (67).
Pat. 2DR−: Sigmoid colon cancer (50)
Moderate or low risk variants
6(6;142) APC c.3920T>A p.(Ile1307Lys) Sigmoid colon cancer (47), IHC = Intact. Mother?: Died <40 years old (non-malignant disease)
Father?: Not CRC.
Pat. 2-4DR: Four CRCs (61–81)?; Sigmoid colon
cancer (58) −; Synchronous ovarian cancer and colon
cancer (50)?
12 (12;82) CHEK2 c.1100delC p.(Thr367Metfs15*) Transverse colon cancer (66), IHC = MLH1/PMS2
absent (MLH1 promoter methylation analysis showed
methylation).
Son?: Rectal cancer (42).
Siblings?: Sigmoid colon cancer (46) and lung cancer
(50); 3 advanced adenomas.
200 (200;10) CHEK2 c.1100delC p.(Thr367Metfs15*) Colon cancer (36), IHC = MSH6 absent. Not CRC in first degree relatives.
55 (55;8) EXO1 c.2212-1G>C p.(?) Sigmoid colon (65), IHC = Intact. Daughter+: Descending colon cancer (36).
Father?: Sigmoid colon (76).
397 (397;10) EXO1
MUTYH
c.2212-1G>C
c.536A>G
p.(?)
p.(Tyr179Cys)
Rectal cancer (31), IHC = n/a. Parents?: Not CRC.
Pat. 2DR?: Leukemia (64).
112 (112;80) GALNT12 c.907G>A p.(Asp303Asn) Rectal cancer (57), IHC = Intact. Father?: Colon cancer (66).
Brother?: Colon sigmoid cancer (50).
Pat. 2DRs?: Prostate cancer (78), melanoma (83), rectal
cancer (84) and 7 adenomas; Ovarian cancer (76) and
bladder cancer 79.
329 (329;10) MUTYH c.536A>G p.(Tyr179Cys) Ascending colon cancer (33), IHC = Intact. No cancers in first- or second-degree relatives.
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families with CRC (3.5%) and variants in PMS2 were identified
in 2/50 patients (4%) from the early onset CRC cohort. A total of
119 variants of unknown significance (VUS) were detected and
are listed in Supplementary Table S1; the 19 most interesting
VUS, based on frequency and CADD scores, are listed in Table 3.
Variant filtering is summarized in Figure 2.
Pathogenic and Likely Pathogenic
High-Risk Variants
The missense variant c.289G>A, p.(Gly97Arg) in APC was
identified in two siblings (no. #14;16 and #14;20) with attenuated
familial adenomatous polyposis (AFAP) phenotype. Segregation
analysis revealed that a third sibling with AFAP also carried the
variant. The variant has previously been reported in a Chinese
patient with mild FAP (Wang et al., 2019). The variant creates
a cryptic acceptor splice site and interrupts normal splicing; this
family and the results of the functional analyses have already been
published (Djursby et al., 2020). Based on these data, we consider
the APC c.289G>A variant likely pathogenic.
One patient (no. #27;10) had a likely pathogenic variant in
POLE: c.1089C>A, p.(Asn363Lys). This variant is not reported
in population allele frequency databases, but has been identified
in two large families with multi tumor phenotypes (Rohlin et al.,
2014; Vande Perre et al., 2019). The variant affects the highly
conserved amino acid Asn-363 in the exonuclease domain of
POLE, and so far only missense variants in this domain have
been confirmed pathogenic (Bellido et al., 2016). Segregation
analysis in the parents on healthy FFPE tissue indicates that the
variant was de novo in our patient, which considerably increases
the pathogenicity of the variant. Family data can be found in
Figure 3, pedigree A. Based on in silico data, our clinical data and
co-segregation data in the two large published families we classify
this variant as likely pathogenic.
We identified two PMS2 variants in two patients with
early onset CRC (no. #309;10 and no. #409;10). The first
PMS2 variant was an indel: c.736_741delinsTGTGTGTGAAG,
p.(Pro246Cysfs∗3). It is categorized as pathogenic by InSiGHT
and has been identified in several Danish patients (Okkels
et al., 2019). The second PMS2 variant was a splice site variant
c.2275+1G>C and has to our knowledge not previously been
reported. To avoid analysis of the PMS2 pseudogenes, the variant
was confirmed using LR-PCR. Immunohistochemical analysis
(IHC) also showed loss of the PMS2 protein in the tumor. Since
the patient is deceased, it has not been possible to perform
mRNA analyses, but the variant is predicted to disrupt normal
splicing completely by five out of five in silico splicing programs
in Alamut, and we consider it to be likely pathogenic.
In family 165 (Figure 3, pedigree B) we identified the MSH2
variant c.2168C>T, p.(Ser723Phe). The variant had already been
detected in the family (Nilbert et al., 2009), but was considered
to be a variant of unknown significance (which is also supported
by InSiGHT classification) and the family was included in this
study to search for alternative explanations. The index person
(no. #165;10), who carries the MSH2 c.2168C>T variant, have
had two primary cancers: Colon cancer (IHC: lack of MSH2
expression, microsatellite instability (MSI) status unknown) and
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TABLE 3 | Selected variants of unknown significance.
Family Gene Transcript variant Protein variant CADD score Impact on splicing* Highest freq. (population)† Allele Count
(homo.)#
Clinvarˆ Comment
408 APC c.2026A>G p.(Ile676Val) 25.200 No 0.0000353 (NFE) 6 (0) C3 (5) Did not have polyposis
338 AXIN2 c.1975C>T p.(Arg659Trp) 33.000 No 0.0006547 (SAS) 66 (0) C2 (1), C3 (2)
20 BLM c.2389G>A p.(Ala797Thr) 32.000 No – –
67 BUB1 c.1457A>G p.(Asp486Gly) 26.900 No – –
162 CDH1 c.2335C>T p.(Arg779Trp) 33.000 No – – C3 (5)
379 CDH1 c.2474C>T p.(Pro825Leu) 25.900 No 0.0000289 (AMR) 4 (0) C3 (5)
69 CHEK2 c.497A>C p.(Asn166Thr) 25.900 No – –
110 CHEK2 c.1427C>T p.(Thr476Met) 25.600 No 0.0005424 (NFE) 77 (0) C3 (8), C4 (10)
7 FOCAD c.3086A>T p.(Tyr1029Phe) 28.700 No 0.0000088 (NFE) 1 (0) Does not segregate in the
family
8 FOCAD c.5376A>T p.(Lys1792Asn) 26.400 No 0.0005643 (NFE) 67 (0) Does not segregate in the
family
406 GALNT12 c.303C>G p.(His101Gln) 25.300 No 0.0003835 (NFE) 23 (0) C3 (2)
309 MLH3 c.1234A>G p.(Lys412Glu) 25.400 No 0.0004564 (NFE) 110 (0) C2 (1) Also has a pathogenic
PMS2 variant366 MLH3 c.3533C>T p.(Pro1178Leu) 27.000 No 0.0000264 (NFE) 3 (0)
344 POLD1 c.961G>A p.(Gly321Ser) 25.400 No 0.0007252 (NFE) 90 (0) C3 (9)
113 POLE c.797G>A p.(Arg266Gln) 26.000 No 0.0000088 (NFE) 1 (0) C3 (2) Located just outside the
END$
92 RPS20 c.98A>T p.(Glu33Val) 26.400 CDS – – Segregates with CRC in the
family
350 SMAD9 c.1161C>A p.(Asn387Lys) 25.200 No 0.0002287 (NFE) 27 (0)
58 SMAD9 c.1171G>A p.(Ala391Thr) 25.200 No 0.0001231 (AFR) 9 (0)
121 TP53 c.814G>A p.(Val272Met) 27.200 No 0.0000088 (NFE) 1 (0) Hematopoietic clone
Variants with a CADD score > 25 and an allele frequency < 0,001 in the population with the highest alternate allele frequency in exomes in gnomAD are listed. BRCA1, BRCA2, CDH1, MMR-, and PTEN variants
categorized as benign or likely benign by expert panels (such as Enigma or InSiGHT) have been discarded. *Impact on splicing was evaluated using Alamut. Only differences in canonical splice site strength >10% (based
on MaxEntScan) was noticed. As for cryptic splice sites, these are only mentioned if at least 4/5 in silico programs indicated that a new splice site was created. CDS, cryptic donor site. †The highest allele frequency in
exomes in gnomAD in any population. NFE, Non-Finnish European; SAS, South Asian; AMR, Latino; AFR, African. #Allele count: Number of alleles with the variant found in exomes in gnomAD. The number in () refers
to the number of homozygous individuals. ∧Clinvar: C2: Likely benign, C3: Uncertain significance, C4: Likely pathogenic. Number in () refers to the number of classifications. $Exonuclease domain.
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FIGURE 2 | Variant filtering. CRC, colorectal cancer; MAF, minor allele frequency; n, number of variants.
an adenocarcinoma at the major duodenal papilla (IHC: lack
of MLH1/PMS2, and methylation of the MLH1 promoter). His
daughter had rectal cancer 25-years-old [IHC: normal, but MSI-
high (MSI-H)] and she also carries the MSH2 variant. His mother
developed colon cancer 44 years-old-old (IHC and MSI status
unavailable), but she does not carry the variant. However, the
family history is complex as the mother is also predisposed to
CRC from another branch of the family, and the father of the
index person died only 31-years-old of non-malignant disease.
Ser-723 is a highly conserved amino acid and the variant is
predicted to be disease causing by several in silico prediction
tools. Several groups have evaluated this variant using in vitro
MMR activity assays, yeast assays or murine or human embryonic
stem cells; all studies indicate that the variant interrupts normal
mismatch repair function and is pathogenic (Gammie et al.,
2007; Drost et al., 2012; Houlleberghs et al., 2016; Rath et al.,
2019). Based on a suggested functional effect in four studies, in
combination with our data with co-segregation in two individuals
with early onset CRC, we consider the MSH2 c.2168C>T variant
likely pathogenic.
Pathogenic and Likely Pathogenic
Moderate and Low Risk Variants
Two patients (no. #329;10 and #397;10) were heterozygous for
the well-established, pathogenic variant in MUTYH c.536A>G,
p.(Tyr179Cys). In APC we detected the frequent c.3920T>A,
p.(Ile1307Lys) variant in a woman with colon cancer at age
47 years (no. #6;142). In CHEK2 we detected the pathogenic
frameshift c.1100del, p.(Thr367Metfs∗15) variant in two patients
(no. #12;82 and #200;10). We identified the GALNT12 variant
c.907G>A, p.(Asp303Asn) in one person (no. #112;80). This
variant has been described several times, and although the role
of GALNT12 in familial cancer is controversial, this particular
variant most likely confers a moderate risk (Guda et al., 2009;
Clarke et al., 2012; Seguí et al., 2014; Lorca et al., 2017; Evans
et al., 2018). In EXO1 we identified the c.2212-1G>C variant in
two individuals (no. #55;8 and #397;10). This variant appears to
confer only a low risk (Jagmohan-Changur et al., 2003; Talseth-
Palmer et al., 2016).
Variants of Unknown Significance
In family 92, a large Amsterdam I positive family with 13 cases
of CRC (IHC analysis in two tumors from two different patients
showed normal expression of the MMR-proteins) in addition
to other cancers, we identified the RPS20 variant c.98A>T,
p.(Glu33Val). This variant is absent from all population allele
frequency databases and has to our knowledge not previously
been reported in the literature. Glu-33 is a highly conserved
amino acid and the variant is predicted to be pathogenic by
several in silico programs and also to affect splicing by four out
of five in silico splicing programs in Alamut by creating a new
cryptic donor site, which may lead to a frameshift due to a loss of
seven base pairs. Segregation analysis showed that five relatives
with CRC from age 24 to 73 years old also carried the variant
(Figure 3, pedigree C).
In one person (#121;10) we identified the likely pathogenic
TP53 variant c.814G>A, p.(Val272Met). The family history
consists of three cases of CRC, two hematological cancers and
one case of prostate cancer; all cancers were diagnosed after age
50 years. The variant had a VAF of 24% in two separate blood
samples suggesting that the variant was either a hematopoietic
clone or a case of classic mosaicism (the patient had the
tumor removed surgically >10 years ago, which almost certainly
excludes circulating tumor DNA from this tumor as a possibility).
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FIGURE 3 | Pedigrees of selected families. (A) Family 27. POLE c.1089C>A, p.(Asn363Lys). (B) Family 165. MSH2 c.2168C>T, p.(Ser723Phe). (C) Family 92.
RPS20 c.98A>T, p.(Glu33Val). Adn., colonic adenomas; BC, breast cancer; CC, colon cancer; CeC, cervical cancer; CeCIS, cervical carcinoma in situ; CRC,
colorectal cancer; GC, gastric cancer; GEJ, malignant gastroesophageal junction tumor; IHC, immunohistochemistry; KC, kidney cancer; LC, lung cancer; MDP,
malignant major duodenal papilla tumor; MM, malignant melanoma; MSI-H, microsatellite instability high; RC, rectal cancer; VC, vulvar cancer; Y.o, years old.
Numbers in parentheses refer to age at diagnosis. + variant carrier, (+) obliged variant carrier (not tested), ? unknown carrier status, ?* unknown carrier status
(analysis failed), −non-carrier.
Frontiers in Genetics | www.frontiersin.org 10 September 2020 | Volume 11 | Article 566266
fgene-11-566266 September 21, 2020 Time: 17:20 # 11
Djursby et al. Genetic Testing of Colorectal Cancer
In order to clarify this issue, we sequenced tumor tissue and
healthy non-malignant tissue; the variant was found in 8% of the
reads in the tumor and was not found in healthy tissue indicating
that the clone most likely represents a hematopoietic clone with
lymphocyte infiltration in the tumor.
We identified six VUS in the MMR genes and eleven VUS
in APC (listed in Supplementary Table S1), of which two
variants – based on allele frequency – are particularly interesting:
MSH6 c.3232G>C, p.(Val1078Leu) and APC c.4318C>T,
p.(Pro1440Ser). The MSH6 c.3232G>C variant was detected in a
patient with CRC from the early onset cohort (no. #329;10), who
also had a pathogenic monoallelic MUTYH variant. The tumor
was microsatellite stable and had normal MSH6 expression,
and along with benign in silico prediction, the variant has a
low probability of being pathogenic. The APC c.4318C>T
variant has not previously been reported and affects a highly
conserved amino acid. The patient (no #1;52) had colon cancer
52-years-old in addition to three small tubular adenomas. He had
two brothers with childhood leukemia and adult-onset serrated
polyposis syndrome, respectively, and is predisposed to CRC on
the paternal side (however, the variant does not segregate with
CRC in a 4th degree paternal relative with CRC 49-years-old and
nine adenomas). According to the family, the maternal family
history is positive with two cases of brain tumors in addition to
a verified case of follicular thyroid carcinoma. Unfortunately, no
functional data on the variant are available.
In one patient (no. #106;10) we identified the BUB1 variant
c.1321A>G, p.(Thr441Ala). The variant is predicted to introduce
a cryptic acceptor splice site 45 base pairs into exon 12 and
could lead to an in-frame loss of 15 amino acids in the protein.
BUB1 variants have in addition to colon cancer been associated
with mosaic variegated aneuploidy syndrome (MVAS), due to
BUB1’s role as a component of the spindle assembly checkpoint,
and dysmorphic features. Data from our patient concerning
dysmorphic features were not available, and the variant does not
segregate with CRC in a 4th degree relative with CRC at age 48.
In FAN1, we identified the frameshift variant c.922_923del,
p.(Val308Cysfs∗5), in a person with metachronous CRC (no.
#143;8), who was a second degree relative in an Amsterdam I
positive family. The variant is reported in exomes in gnomAD
with an allele frequency of 0.023% in non-Finnish Europeans and
has been classified as likely pathogenic in ClinVar. However, the
variant does not segregate with another case of rectal cancer at age
49 or a case of cancer with unknown origin at age 59 in the family.
In addition, we identified several missense variants in CHEK2
and one in POLD1 that might have a moderate impact on
CRC risk (Table 3).
Monoallelic Pathogenic Variants in
Genes With Autosomal Recessive
Inheritance
We detected the previously reported NTHL1 nonsense variant
c.268C>T, p.Gln90∗ in one patient (no. #136;12). To our
knowledge, the significance of monoallelic, pathogenic NTHL1
variants is currently unknown (Weren et al., 2015). Another
patient (no. #84;14) was heterozygous for the likely pathogenic
MSH3 variant c.2319-1G>A (Adam et al., 2016). The patient
also carried a second MSH3 intron variant, c.2436-13G>T not
predicted to affect splicing by in silico analysis (Alamut). Due to
the method (short read sequencing) used in this study, it was
not possible to unravel if the variants are in cis or trans. Since
MSH3-related CRC is inherited in an autosomal recessive pattern,
the variants cannot explain the apparently dominant inheritance
pattern in the family.
DISCUSSION
In this study, we performed gene panel analysis of 32 CRC
associated genes in two cohorts of patients: (1). Patients with early
onset CRC (n = 50) and (2). Patients from families with familial
CRC (n = 99 patients from 85 families). The great majority of
patients had MMR-proficient tumors, based on IHC analysis, and
all patients (n = 7) from the familial CRC cohort with abnormal
IHC expression had a relative with normal IHC analysis. This was
consistent with the results of previous genetic testing of the MMR
genes where ∼90% of the participants, or an affected relative,
had had MMR analysis performed without identification of a
pathogenic or likely pathogenic variant (Table 1).
In the cohort with familial CRC we identified three high-
risk pathogenic variants in APC, MSH2 and POLE. The
MSH2 variant, c.2168C>T, p.(Ser723Phe) had previously been
identified, but since new knowledge have emerged, the variant
was reclassified to a likely pathogenic variant from a VUS.
The likely pathogenic APC variant c.289G>A, p.(Gly97Arg)
was – for reasons unknown – not identified or interpreted as
pathogenic when APC analysis was performed 20 years ago, but
since the family fulfils APC-testing criteria the variant would
normally have been detected through routine genetic handling.
The APC-screening was originally performed using only Sanger
sequencing, and these two cases emphasize the importance of
a regular reassessment of genetically unresolved families with
apparently inherited cancer with either a reassessment of variants
of unknown significance or repeated NGS-based analyses. The
POLE c.1089C>A, p.(Asn363Lys) variant was found in an
Amsterdam I positive family, where two affected persons turned
out to be phenocopies. They had milder phenotypes with only
one tumor at a higher age (67 and 50 years old, respectively)
compared to three syn- and metachronous CRCs at age 28 and
40 in the index patient. This case clearly illustrates the great
importance of choosing the most severely affected family member
for genetic analysis.
Thus, although we identified pathogenic variants in 8 families
out 85 families (9.4%) only three variants were clinically
actionable and two variants were, or should have been,
detected previously.
In the early onset cohort, we identified two pathogenic/likely
pathogenic PMS2 variants in addition to several low or moderate
risk variant including a pathogenic MUTYH variant, identified
in two unrelated CRC patients. The clinical impact of pathogenic
PMS2 variants are currently debated, but it is widely accepted that
PMS2 variants confer a much lower cancer risk than the other
MMR genes. For now, however, the families are being handled as
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classic Lynch Syndrome families. Monoallelic MUTYH variants
are associated with a ∼two-fold risk of developing CRC,
and in Denmark carriers of monoallelic pathogenic MUTYH
variants, who have a first-degree relative with CRC, are offered
colonoscopy surveillance every 5 years. Thus, the diagnostic yield
of clinically actionable variants in the early onset cohort were 8%
(4 out of 50 patients).
The genetic background of CRC for a large proportion of
the patients in our study is still unresolved, which can have
several explanations.
Firstly, our gene panel consisted of only CRC-related genes,
and we might have had a higher diagnostic yield if our gene panel
had included more known cancer predisposition genes.
Secondly, we did not include copy number variation (CNV)
analysis in our study. CNVs have been estimated to account for
up to 10% of all pathogenic variants (with great differences from
gene to gene) suggesting that we might have missed et least one
or a few CNVs in our cohort (LaDuca et al., 2019). Clinical follow
up on the patients revealed that one patient actually had been
diagnosed with juvenile polyposis syndrome due to a deletion of
exon 9 to 10 in SMAD4. She developed colon cancer at age 36 and
had had three colonic adenomas removed (one with high grade
dysplasia). After the diagnosis she had another polyp removed
which was interpreted as either an inflammatory or a juvenile
polyp. In total, about one out of three patients had had CNV
analysis performed in a clinical setting, but no further CNVs
had been detected (unpublished data). The SMAD4 case also
exemplifies the overlapping features of CRC-related syndromes:
The patient was highly suspicious of having HNPCC/Lynch
Syndrome but ended up with a diagnosis of juvenile polyposis.
Thirdly, some patients probably have pathogenic variants
in regions that our analysis was not designed to capture,
such as deep intronic or regulatory variants in known cancer
genes or variants in genes not yet identified or associated with
CRC. Many genes have been suggested as candidate colorectal
genes, and especially genes such as POLE2, MRE11, and POT1
appear to be interesting genes as well as epigenetic changes
in PTPRJ (Venkatachalam et al., 2010; Chubb et al., 2016;
Terradas et al., 2020). Another possibility is a non-mendelian
predisposition to CRC. Polygenic inheritance has been shown
to explain up to ∼15% of the familial CRC risk (Frampton
et al., 2016) and at least two cases with CRC and possible
digenic and oligogenic inheritance have been reported; these
patients had variants in MUTYH and OGG1 (both involved
in the base excision repair pathway) and in APC, OGG1,
EXO1 and POLQ, respectively (Morak et al., 2011; Ciavarella
et al., 2018). OGG1 was not part of our gene panel, and
its role in hereditary CRC/polyposis is controversial (Smith
et al., 2013; Mur et al., 2018). Intriguingly, we identified the
same EXO1 variant in a patient with rectal cancer 31-years-
old (no. 397;10) from the early onset CRC cohort who also
carried a monoallelic, pathogenic MUTYH variant. Although
EXO1 (mainly involved in mismatch repair) and MUTYH
(mainly involved in base excision repair) are not involved
in the same pathway, they are both involved in DNA repair
pathways. In order to reveal if she had other low or moderate
risk variants – and thus could represent a case of oligogenic
inheritance – we plan to perform whole genome sequencing
(WGS) as next step.
As expected, we detected a high number of VUS, and
some may – as more data become available – be reclassified
as either class 1/2 or 4/5. An example of a VUS with a
high potential of being reclassified to (likely) pathogenic is
the RPS20, c.98A>T, p.(Glu33Val), variant. Only two families,
one large family with multiple cases of CRC and a truncating
RPS20 variant (c.147dupA, p.Val50SerfsTer23), and one small
family with a splice site variant shown to disturb normal
splicing (c.177+1G>A), have been reported in addition to two
individuals with early onset CRC and without published family
cancer history (Nieminen et al., 2014; Broderick et al., 2017;
Thompson et al., 2020). The latter individuals had a missense
variant, p.Val54Leu, and a frameshift variant, p.Leu61GlufsTer11,
respectively. All analyzed tumors, including those in our family,
have shown MMR-proficient tumor phenotype based on IHC
analysis. RPS20 encodes a ribosomal protein which is a part of
the S40 subunit. RPS20 has been suggested to be involved in cell
proliferation and regulation, and as a stabilizer of p53 (Nieminen
et al., 2014) but recently Krishnan et al. (2018) provided evidence
of a critical interaction between RPS20 and GNL1 – a nucleolar
ATPase also involved in cell cycle regulation – which regulates
and promotes the G1/S phase, and thus provided documentation
of a possible link to tumorigenesis. Several factors support that
the c.98A>T variant is pathogenic: Strong segregation analysis
in the family presented in our study, in silico splicing prediction
and the fact that the variant has not previously been reported
or cataloged in gnomAD. RPS20 is a very promising colorectal
candidate gene, and the identification of three families with
variants segregating with disease is strong evidence. However,
since the role of RPS20 in CRC is not yet fully established,
we categorize the variant as a VUS. Three out of four of the
previously published variants in RPS20 were located in exon
3 or close to exon 3/4 boundaries. These variants have only
been associated with CRC. The variant identified in the family
presented in our study were located in exon 2 (close to the exon
2/intron 2 junction), and this family has a pedigree with 12 cases
of CRC, but also other cancer types such as early onset vulva
cancer, melanoma, breast cancer and esophageal/gastric cancer
(Figure 2, pedigree C). Our family also has the by far youngest
affected RPS20 carrier, a female who was diagnosed with CRC 24-
years-old. The other families also had early onset CRC cases at
age 38, 39, and 41 respectively. Nieminen et al. (2014) did not
provide detailed data on age at onset, but the mean age at onset of
CRC were 52.3 years. Due to the scarcity of families with RPS20
variants, data on genotype-phenotype correlations are premature,
but if the c.98A>T variant turns out to be pathogenic it will not
only confirm the role of RPS20 in hereditary CRC, but it will
also expand the phenotypic spectrum of RPS20 related cancer
significantly. Due to the very high probability of RPS20 truly
being a new cancer gene, we recommend inclusion of RPS20 in
cancer gene panels.
An example of a complicated VUS is the TP53 c.814G>A
variant. The family does not meet TP53 testing criteria [i.e., the
2015 version of the Chompret Criteria (Bougeard et al., 2015)]
and the variant was solely identified because our multigene panel
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analysis was performed. TP53 variants with a reduced mutant to
wild-type allele ratio (MWTAR), for example <25% or 30%, are
a common issue when analyzing multi gene panels as discussed
by Weitzel et al. (2018); their study also showed that TP53
variants with reduced MWTAR were more likely to represent
hematopoietic clones when identified in multigene panels and in
older patients, which was also the case in our family.
We detected several other pathogenic and interesting VUS
in moderate penetrance genes such as CHEK2 and GALNT12,
however, until we have reached a better understanding of
the consequences of combinations of low- and moderate risk
variants, we consider genetic testing of these genes in a clinical
setting premature.
We identified only one variant in FAN1 with an allele
frequency of <0.1%, namely the c.922_923del variant. The
variant has been published in two patients with a suspected
genetic predisposition to cancer but neither first- or second-
degree-relatives were affected by CRC (Fievet et al., 2019). FAN1
was proposed to be a CRC candidate gene in 2015 (Seguí et al.,
2015), but the evidence of its role in hereditary CRC is still very
limited (Broderick et al., 2017; Fievet et al., 2019). Our data
further questions the role of FAN1 in hereditary cancer, and like
Fievet et al. (2019), we also suggest excluding this gene from
cancer gene panels.
In general, our study – a retrospective cohort study consisting
primarily of highly selected MMR-proficient individuals –
showed the highest diagnostic hit rate in families with a high
burden of adenomas or with an exceptionally early age at onset.
The youngest variant carriers with CRC in the families with
(possible) high-risk variants were diagnosed with CRC at a
mean of 28.4 years (age 28 (POLE, c. 1089C>A), 25 (MSH2,
c.2168C>T), 29 (PMS2, c.736_741delinsTGTGTGTGAAG), 36
(PMS2, c.2275+1G>C) and 24 (RPS20, c.98A>T) compared to
an average age of 40.5 years of the youngest person diagnosed
with CRC in the rest of the participant’s families (only 1st to 3rd
degree relatives are included). In total, only eight families had a
person with CRC before age 30, and we found a (possible) genetic
explanation in 50%. Thus, when reevaluating families/patients
with previous MMR-analysis and without polyposis, our data
suggest that a limited number of genes – such as APC
(primarily in order to identify AFAP families) and MUTYH
(due to the high population carrier frequency) – is sufficient
to capture the majority of families with a hereditary cancer
predisposition syndrome. The exception appears to be when very
early onset cases of CRC have occurred, and also if the personal
history or family history suggests a syndromic etiology such as
Peutz-Jeghers syndrome, juvenile polyposis syndrome, Cowden
syndrome etc. The age limit of very early onset CRC is arbitrary,
but a proposal could be age 40. These families would benefit from
a larger gene panel analysis.
Since most patients referred for genetic evaluation have
not been genetic tested previously, the approach in these
families needs to be different. In Denmark – with a public
health care system allowing all citizens access to relevant
health care regardless of income/insurance – both cohorts are
eligible for genetic counseling and -testing and the majority are
offered analysis of a clinical CRC gene panel consisting of 17
CRC and polyposis related genes (as described in the section
“Introduction”). The Collaborative Group of the Americas
on Inherited Gastrointestinal Cancer recently published a
recommendation regarding gene panel testing in hereditary CRC
or polyposis, and they recommend that multigene testing as a
minimum includes the MMR-genes, EPCAM, APC, MUTYH,
BMPR1A, SMAD4, PTEN and STK11 (Heald et al., 2020).
Although some of the genes are primarily relevant in case of
polyposis (PMPR1A, SMAD4, PTEN, STK11), implementation
of this gene panel would probably be the approach with lowest
costs. Another approach is testing of one large cancer gene
panel irrespective of phenotype. Studies analyzing very large
cancer gene panels, not based on phenotype, have widened the
phenotypic spectra for a number of cancer genes (Espenschied
et al., 2017; Rohlin et al., 2017; LaDuca et al., 2019) and
this approach would also catch rare causes of CRC. Although
large gene panels generate more VUS that can be challenging
to interpret and handle clinically, they are more efficient in
terms of price and time. A third and fourth approach is
targeted WES or WGS, respectively. WGS has the advantage of
generating the greatest amount of data including (i) promoter,
regulatory and deep intronic variants, which is very relevant
to look for in established cancer genes (ii) reliable CNV
data, (iii) data on structural rearrangements (iv) data on all
SNPs making it possible to calculate polygenic risk scores, and
(v) readily available data on new genes/variants when new
knowledge comes forth. On the other hand, WGS is the most
expensive and time-consuming analysis (when it comes to variant
interpretation). Costs of WGS are currently approaching those
of WES, but both are high-cost approaches, and the gray zone
between clinical evaluation and research, as well as the ethical
dilemmas of performing large genomic analyses, are issues
which should be discussed. A paradigm shift from phenotype-
based cancer gene panels to larger genomic analyses seems
inevitable though.
The combination of young age at onset and a lack of CRC in
the family history would suggest recessive inheritance or high-
risk de novo variants, and the complete lack of other high-risk
variants than the PMS2 variants in our early onset CRC cohort
was unexpected. In the familial cancer cohorts, a number of
the families are indeed highly suspicious of having a genetic
cancer syndrome, and although novel cancer genes probably
only account for a very small percentage of cases (Chubb et al.,
2016) further studies are warranted in order to elucidate the
genetic background of hereditary cancer and to identify novel
cancer genes. In order to search for other explanations in our
cohorts, selected individuals are now undergoing WGS, which
will hopefully help to clarify the disease-causing mechanisms in a
larger proportion of the individuals.
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